Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rina Plattner

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Science Signaling|February 22, 2018
Abl and Arg mediate cysteine cathepsin secretion to facilitate melanoma invasion and metastasisRakshamani Tripathi, Leann S Fiore, Dana L Richards, et al.
Biochemical Pharmacology|May 12, 2009
STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific mannerJonathan T Sims, Sourik Ganguly, Leann S Fiore, et al.
Frontiers in Genetics|November 7, 2022
Inhibition of ABL1 by tyrosine kinase inhibitors leads to a downregulation of MLH1 by Hsp70-mediated lysosomal protein degradationHannah G Daniels, Breanna G Knicely, Anna Kristin Miller, et al.
Cancers|April 30, 2021
KEAP1 Is Required for Artesunate Anticancer Activity in Non-Small-Cell Lung CancerKristen S Hill, Anthony McDowell, J Robert McCorkle, et al.
Nature Cell Biology|March 26, 2003
A new link between the c-Abl tyrosine kinase and phosphoinositide signalling through PLC-gamma1Rina Plattner, Brenda J Irvin, Shuling Guo, et al.
Cancer Causes & Control : CCC|November 30, 2018
Potential protein markers for breast cancer recurrence: a retrospective cohort studyChunyan He, Rina Plattner, Vivek Rangnekar, et al.
Cancers|February 11, 2023
ABL1/2 and DDR1 Drive MEKi Resistance in NRAS-Mutant Melanomas by Stabilizing RAF/MYC/ETS1 and Promoting RAF HomodimerizationAnastasia Lyon, Rakshamani Tripathi, Christina Meeks, et al.
Nature Communications|October 30, 2020
Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signalingRakshamani Tripathi, Zulong Liu, Aditi Jain, et al.
Oncogene|October 8, 2013
c-Abl and Arg induce cathepsin-mediated lysosomal degradation of the NM23-H1 metastasis suppressor in invasive cancerLeann S Fiore, Sourik S Ganguly, James Sledziona, et al.
Neoplasia (New York, N.Y.)|March 18, 2010
Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancerHuajun Zhao, Fu Ou-Yang, I-Fen Chen, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Science Signaling|February 22, 2018
Abl and Arg mediate cysteine cathepsin secretion to facilitate melanoma invasion and metastasisRakshamani Tripathi, Leann S Fiore, Dana L Richards, et al.
Biochemical Pharmacology|May 12, 2009
STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific mannerJonathan T Sims, Sourik Ganguly, Leann S Fiore, et al.
Frontiers in Genetics|November 7, 2022
Inhibition of ABL1 by tyrosine kinase inhibitors leads to a downregulation of MLH1 by Hsp70-mediated lysosomal protein degradationHannah G Daniels, Breanna G Knicely, Anna Kristin Miller, et al.
Cancers|April 30, 2021
KEAP1 Is Required for Artesunate Anticancer Activity in Non-Small-Cell Lung CancerKristen S Hill, Anthony McDowell, J Robert McCorkle, et al.
Nature Cell Biology|March 26, 2003
A new link between the c-Abl tyrosine kinase and phosphoinositide signalling through PLC-gamma1Rina Plattner, Brenda J Irvin, Shuling Guo, et al.
Cancer Causes & Control : CCC|November 30, 2018
Potential protein markers for breast cancer recurrence: a retrospective cohort studyChunyan He, Rina Plattner, Vivek Rangnekar, et al.
Cancers|February 11, 2023
ABL1/2 and DDR1 Drive MEKi Resistance in NRAS-Mutant Melanomas by Stabilizing RAF/MYC/ETS1 and Promoting RAF HomodimerizationAnastasia Lyon, Rakshamani Tripathi, Christina Meeks, et al.
Nature Communications|October 30, 2020
Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signalingRakshamani Tripathi, Zulong Liu, Aditi Jain, et al.
Oncogene|October 8, 2013
c-Abl and Arg induce cathepsin-mediated lysosomal degradation of the NM23-H1 metastasis suppressor in invasive cancerLeann S Fiore, Sourik S Ganguly, James Sledziona, et al.
Neoplasia (New York, N.Y.)|March 18, 2010
Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancerHuajun Zhao, Fu Ou-Yang, I-Fen Chen, et al.
Pageof 3